Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world
See the original post here:
First stem cell drug approved for systemic disease treatment
Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.
Read the rest here:
Health Canada approves Osiris’ Prochymal to treat acute GvHD in children
California Stem Cell, Inc. announced today that well-known stem cell & regenerative medicine industry veteran Gregory A. Bonfiglio, J.D. has joined its Board of Directors
Read more from the original source:
Industry Consultant Gregory Bonfiglio Joins California Stem Cell Board of Directors
One of the first long-term studies of stem cell treatment for spinal cord injury shows significant functional and other improvements in three out of ten patients, reports a study in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Here is the original post:
Stem Cells for Spinal Cord Injury: Some Patients Have Long-Term Improvement
BOSTON (MarketWatch) — Shares of Osiris Therapeutics jumped 14% to $5.60 in after-hours trading Thursday on news that Canadian regulators have approved its product Prochymal for the treatment of acute graft-vs-host disease, or GVHD, in children. GVHD is a life-threatening complication associated with such procedures as bone-marrow transplantation. Osiris added it was the world's first …
BOSTON (Reuters) – Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Graft versus host disease (GvHD) is a …
See the original post here:
Canada OKs Osiris drug; first stem cell therapy
Osiris Therapeutics Inc says Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. read more
More here:
Canada approves stem cell therapy
Osiris Therapeutics Inc. (OSIR) said it won the world’s first approval for a stem-cell drug, gaining clearance in Canada to sell Prochymal for a disease that can attack patients who received bone-marrow transplants.
More:
Osiris Wins Canadian Approval for First Stem-Cell Therapy
Osiris Therapeutics Inc. said Thursday that Canadian regulators approved its stem cell therapy Prochymal, which is intended to treat a deadly side effect of bone marrow transplants.
See the article here:
Osiris stem cell therapy approved in Canada
Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal® , for the treatment of acute graft-vs-host disease in children.
Continued here:
World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal
Fair Use Disclaimer
"Congress shall make no law respecting an establishment of religion,
or prohibiting the free exercise thereof; or abridging the freedom of
speech, or of the press; or the right of the people peaceably to
assemble, and to petition the government for a redress of grievances."
Under the 'fair use' rule of copyright law, an author may make limited use of another author's work without asking permission. Fair use is based on the belief that the public is entitled to freely use portions of copyrighted materials for purposes of commentary and criticism. The fair use privilege is perhaps the most significant limitation on a copyright owner's exclusive rights.
Fair use as described at 17 U.S.C. Section 107:
"Notwithstanding the provisions of section 106 and 106A, the fair use of a copyrighted work, including such use by reproduction in copies or phono-records or by any other means specified by that section, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright.
In determining whether the use made of a work in any particular case is a fair use the factors to be considered shall include:
